Top Banner
Addressing Current Challenges in Preventing and Managing Neutropenia in Cancer
19

Addressing Current Challenges in Preventing and Managing Neutropenia in Cancer

Jan 04, 2016

Download

Documents

marilu alfaro

Addressing Current Challenges in Preventing and Managing Neutropenia in Cancer. Program goals. Neutropenia Overview. Febrile Neutropenia. Myeloid Growth Factors. Adverse Effects of Filgrastim and Derivatives. Tbo-filgrastim. - PowerPoint PPT Presentation
Welcome message from author
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
Page 1: Addressing Current Challenges in Preventing and Managing Neutropenia in Cancer

Addressing Current Challenges in Preventing and Managing

Neutropenia in Cancer

Page 2: Addressing Current Challenges in Preventing and Managing Neutropenia in Cancer
Page 3: Addressing Current Challenges in Preventing and Managing Neutropenia in Cancer

Program goals

Page 4: Addressing Current Challenges in Preventing and Managing Neutropenia in Cancer

Neutropenia Overview

Page 5: Addressing Current Challenges in Preventing and Managing Neutropenia in Cancer

Febrile Neutropenia

Page 6: Addressing Current Challenges in Preventing and Managing Neutropenia in Cancer

Myeloid Growth Factors

Page 7: Addressing Current Challenges in Preventing and Managing Neutropenia in Cancer

Adverse Effects of Filgrastim and Derivatives

Page 8: Addressing Current Challenges in Preventing and Managing Neutropenia in Cancer

Tbo-filgrastim

Page 9: Addressing Current Challenges in Preventing and Managing Neutropenia in Cancer

Prevention of Febrile Neutropenia With CSFs

Assess Risk from Chemotherapy Regimen

Page 10: Addressing Current Challenges in Preventing and Managing Neutropenia in Cancer

Prevention of Febrile Neutropenia With CSFs

Assess Patient Risk Factors

Page 11: Addressing Current Challenges in Preventing and Managing Neutropenia in Cancer

Developing a Model to Assess Risk

Page 12: Addressing Current Challenges in Preventing and Managing Neutropenia in Cancer

Administration Issues

Page 13: Addressing Current Challenges in Preventing and Managing Neutropenia in Cancer

Pharmacoeconomic Considerations

Page 14: Addressing Current Challenges in Preventing and Managing Neutropenia in Cancer

Agent Specifics

Page 15: Addressing Current Challenges in Preventing and Managing Neutropenia in Cancer

Summary

Page 16: Addressing Current Challenges in Preventing and Managing Neutropenia in Cancer

Abbreviations

Page 17: Addressing Current Challenges in Preventing and Managing Neutropenia in Cancer

References

Page 18: Addressing Current Challenges in Preventing and Managing Neutropenia in Cancer

References (cont)

Page 19: Addressing Current Challenges in Preventing and Managing Neutropenia in Cancer

References (cont)